Breastfeeding moms needed for HIV drug study
NCT ID NCT06580587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 study tested how the experimental HIV prevention drug MK-8527 moves into breast milk. Thirteen healthy lactating women took a single oral dose, then provided milk and blood samples over five days. The goal was to measure how much drug reaches the baby through breastfeeding, which is important for future safe use in HIV prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-8527
What this could lead to
If successful, this study could help determine safe dosing of MK-8527 for HIV prevention in breastfeeding women.
What could go wrong
This is a very early Phase 1 study with only 13 participants. It measures drug levels, not effectiveness or safety for the baby.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PRE-EXPOSURE PROPHYLAXIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
Springfield, Missouri, 65802, United States
-
University of Pittsburgh Medical Center Magee-Womens Hospital ( Site 0001)
Pittsburgh, Pennsylvania, 15213, United States